Appendix Table 2.
Demographics for Primary and Secondary Sensitivity Analysis
| PRIMARY SENSITIVITY ANALYSIS | SECONDARY SENSITIVITY ANALYSIS | |||
|---|---|---|---|---|
| VARIABLE | ELECTIVE SURGERY N = 634 |
MEDICAL THERAPY† N = 5,665 |
ELECTIVE SURGERY N = 474 |
MEDICAL THERAPY† N = 3,533 |
| Age, n (%)* | ||||
| 18 ≤ age < 30 | 38 (6) | 320 (6) | 35 (7) | 286 (8) |
| 30 ≤ age < 40 | 60 (10) | 495 (9) | 43 (9) | 298 (8) |
| 40 ≤ age < 45 | 28 (4) | 236 (4) | 17 (4) | 109 (3) |
| 45 ≤ age < 50 | 27 (4) | 234 (4) | 19 (4) | 134 (4) |
| 50 ≤ age < 55 | 27 (4) | 224 (4) | 18 (4) | 121 (3) |
| 55 ≤ age < 60 | 28 (4) | 224 (4) | 19 (4) | 111 (3) |
| 60 ≤ age < 65 | 24 (4) | 172 (3) | 17 (4) | 98 (3) |
| 65 ≤ age < 70 | 127 (20) | 1,174 (21) | 101 (21) | 821 (23) |
| 70 ≤ age < 75 | 128 (20) | 1,209 (21) | 96 (20) | 747 (21) |
| 75 ≤ age < 80 | 91 (14) | 833 (15) | 69 (15) | 519 (15) |
| ≥ 80 | 56 (9) | 544 (10) | 40 (8) | 289 (8) |
| Gender, n (%)* | ||||
| Female | 372 (59) | 3,377 (60) | 267 (56) | 2,025 (57) |
| Male | 262 (41) | 2,288 (40) | 207 (44) | 1,508 (43) |
| Medication use in prior 180 days, n (%)* | ||||
| Corticosteroids | 334 (53) | 2,808 (50) | 334 (71) | 2,766 (78) |
| Cyclosporine/Tacrolimus | <11 (<1)** | <11 (<1)** | <11 (<1)** | <11 (<1)** |
| Azathioprine/6-MP | 157 (25) | 1,119 (20) | 157 (33) | 1,112 (32) |
| Infliximab | 63 (10) | 411 (7) | 63 (13) | 408 (12) |
| Hospitalized for UC, n (%)* | 322 (51) | 2,863 (51) | 207 (44) | 1,339 (40) |
| Days from cohort entry to start of follow-up* | ||||
| Mean (SD) | 396 (445) | 376 (426) | 372 (398) | 328 (348) |
| Median (IQR) | 231 (68–619) | 212 (62–572) | 217 (88–549) | 184 (77–478) |
| Medicaid beneficiary, n (%)* | 250 (39) | 2,175 (38) | 184 (39) | 1,337 (38) |
| Comorbidity score (preceding 180 days) | ||||
| Score > 1 | 266 (42) | 1,691 (30) | 184 (39) | 972 (28) |
| Mean (SD) | 1.7 (2) | 1.2 (2) | 1.5 (2) | 1.1 (2) |
| Median (IQR) | 1.0 (0–3.0) | 1.0 (0–2.0) | 1.0 (0–3.0) | 0 (0–2.0) |
| Non-IBD medications in prior 180 days | ||||
| mean (SD) | 10 (5) | 10 (5) | 11 (5) | 10 (5) |
| median (IQR) | 10 (6–13) | 9 (6–12) | 10 (7–14) | 9 (6–13) |
| Emergency Department visits in prior 180 days | ||||
| mean (SD) | 0.9 (1.6) | 0.8 (1.7) | 0.9 (1.7) | 0.7 (1.6) |
| median (IQR) | 0 (0–1.0) | 0 (0–1.0) | 0 (0–1.0) | 0 (0–1.0) |
†
Not all medical therapy patients had exposure to immunosuppressants or corticosteroids in the 180-days prior to follow-up; some had exposure to mesalamine therapy or had no medication exposure (and were removed in the secondary sensitivity analysis)
*
Medical therapy patients were weighted in the analysis according to the number of patients in each matched group. The numbers reported here are not weighted and do not reflect the balance achieved with the matching.
**
Use of the data was governed by a Data Use Agreement with CMS, which prohibits displaying any cell size < 11.